Notable Healthtech Investments From AV’s Portfolio
American Gene Technologies and SonderMind demonstrate our ability to secure investments in high-potential healthtech opportunities
Below are case studies on two notable healthtech investments from Alumni Ventures’ portfolio. American Gene Technologies is developing and commercializing genetic medicines targeting major diseases, while SonderMind is a behavioral health network addressing the three-sided marketplace between consumers, therapists, and enterprise partners. Both companies demonstrate our ability to identify and secure investments in high-potential healthtech opportunities, which we’ll aim to do for this year’s Healthtech Fund. Investors in the fund will own a diversified portfolio of ~20-30 companies developing impactful healthtech and biotech solutions to address addiction, obesity, Alzheimer’s, cancer, genomics, longevity, and more.
American Gene Technologies (AGT) is developing and commercializing genetic medicines targeting major diseases, including HIV/AIDS, phenylketonuria, and hepatocellular carcinoma (liver cancer, or HCC). AGT’s drugs will treat symptomatic disease with the intent to provide durable cures that extend the length and improve the quality of patients’ lives. We invested in AGT’s $15 million Series D in 2018 alongside Swirnow Capital and Thompson Holdings.
SonderMind is a behavioral health network addressing the three-sided marketplace between consumers, therapists, and enterprise partners. Powered by an expert team and data-driven insights, the company has created a robust software platform that provides users with reliable access to a variety of mental health services. We first invested in the company’s $2.5 million Seed in 2018 and most recently participated in a $150 million Series C in 2021, co-led by Drive Capital and Premji Invest and raised at a valuation “well north” of $1 billion.
Healthtech Fund Open Through Q2 2023
Our Healthtech Fund will invest in a diversified portfolio of ~20-30 companies applying secure record digitization, telemedicine, big data, genomics, and real-time monitoring via wearable devices. The fund will be invested over ~12-18 months, with a large reserve (~20-25%) for follow-ons. Every investor becomes a member of the Healthtech Venture Club, with opportunities to invest in Syndications, learn, and network.
Click below to review fund materials or connect with a Senior Partner.
Contact [email protected] for additional information. To see additional risk factors and investment considerations, visit av-funds.com/disclosures.
NOTE: For illustration purposes only. These investments are not intended to suggest any level of investment returns; not necessarily indicative of investments invested by any single fund or investor. Many returns in investments result in the loss of capital invested. These investments are not available to future fund investors except potentially in certain follow-on investment options.